DRI Healthcare Trust Maintains Buy Rating From Stifel GMP as It Adds a New Drug Royalty; Price Target Kept at C$20.00
DRI Healthcare Trust Maintains Buy Rating From Stifel GMP as It Adds a New Drug Royalty; Price Target Kept at C$20.00
DRI Healthcare Trust 維持Stifel GMP的買入評級，因爲它增加了新的藥品特許權使用費；目標股價維持在20.00加元
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊